Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Publication ,  Journal Article
Soubrane, C; Mouawad, R; Ichen, M; Suissa, J; Borel, C; Vuillemin, E; Benhammouda, A; Bizzari, JP; Weil, M; Khayat, D
Published in: Clin Exp Immunol
February 1994

Immunological parameters following chemoimmunotherapy combination were studied in 31 patients with metastatic malignant melanoma. They received Cisplatin (100 mg/m2) on day 1 and 28, recombinant IL-2 (rIL-2; Eurocetus) in continuous infusion from day 3 to 6, 17 to 21, 31 to 34 and 45 to 49. Interferon-alpha (IFN-alpha; Roche) was given subcutaneously three times weekly. No significant change in CD4/CD8 ratio at onset or during treatment was observed between responder (n = 19) and non-responder (n = 12) patients. Regarding the IL-2 receptor (IL-2R) study, the percentage of cells expressing Tac (p55) receptor did not change either for healthy volunteers (n = 20) and patients before any therapy, or between responder and non-responder patients. Concerning serum soluble IL-2R shedding before therapy, we observed a significant increase (P = 0.001) in patients (79 +/- 40 pM) compared with healthy donors (30 +/- 15 pM), but no significant variation was seen between responder and non-responder patients. In contrast, during the treatment, the soluble IL-2R level increased in both groups but, interestingly, a significant difference was found between responder and non-responder patients from day 7 (P < 0.05) to day 21 (P < or = 0.01), suggesting that the cells from non-responder may be slower in becoming stimulated. This finding is the most striking point of our study and suggests that sIL-2R might be an early predictive factor of the clinical response as obtained by logistic regression (P = 0.0063). Therefore patients with a serum soluble IL-2R level greater than 250 pM at day 21 have a 12-fold more chance of undergoing a clinical response.

Duke Scholars

Published In

Clin Exp Immunol

DOI

ISSN

0009-9104

Publication Date

February 1994

Volume

95

Issue

2

Start / End Page

232 / 236

Location

England

Related Subject Headings

  • Receptors, Interleukin-2
  • Middle Aged
  • Melanoma
  • Male
  • Interleukin-2
  • Interferon-alpha
  • Immunophenotyping
  • Immunology
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Soubrane, C., Mouawad, R., Ichen, M., Suissa, J., Borel, C., Vuillemin, E., … Khayat, D. (1994). Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol, 95(2), 232–236. https://doi.org/10.1111/j.1365-2249.1994.tb06516.x
Soubrane, C., R. Mouawad, M. Ichen, J. Suissa, C. Borel, E. Vuillemin, A. Benhammouda, J. P. Bizzari, M. Weil, and D. Khayat. “Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.Clin Exp Immunol 95, no. 2 (February 1994): 232–36. https://doi.org/10.1111/j.1365-2249.1994.tb06516.x.
Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E, et al. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol. 1994 Feb;95(2):232–6.
Soubrane, C., et al. “Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.Clin Exp Immunol, vol. 95, no. 2, Feb. 1994, pp. 232–36. Pubmed, doi:10.1111/j.1365-2249.1994.tb06516.x.
Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E, Benhammouda A, Bizzari JP, Weil M, Khayat D. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol. 1994 Feb;95(2):232–236.
Journal cover image

Published In

Clin Exp Immunol

DOI

ISSN

0009-9104

Publication Date

February 1994

Volume

95

Issue

2

Start / End Page

232 / 236

Location

England

Related Subject Headings

  • Receptors, Interleukin-2
  • Middle Aged
  • Melanoma
  • Male
  • Interleukin-2
  • Interferon-alpha
  • Immunophenotyping
  • Immunology
  • Humans
  • Follow-Up Studies